Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Date publication

janvier 2019

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr MOUILLET Guillaume

Tous les auteurs :
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30616146

Résumé

Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for naïve patients with intermediate or poor risk prognosis (International mRCC Database Consortium). The efficacy of subsequent vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) after nivolumab-ipilimumab failure remains unclear.

Mots clés

Immunotherapy, Ipilimumab, Metastatic renal cell carcinomas, Nivolumab, Outcomes, Second-line tyrosine kinase inhibitors

Référence

Eur. J. Cancer. 2019 Jan 4;108:33-40